Pertussis

FDA Licenses Acellular Pertussis Vaccine for Infant Use

Published in Vaccine Weekly, November 11th, 1996

The U.S. Food and Drug Administration (FDA) licensed the Tripedia (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) vaccine for use in infants two, four, and six months of age and for the first booster dose at 15 to 20 months.

Tripedia (Connaught Laboratories, Inc., Swiftwater, Pennsylvania) has been licensed in the U.S. for the fourth and fifth doses for immunization of children 15 months to seven years of age (prior to seventh birthday) who previously have received three doses of whole cell DTP vaccine.

Tripedia acellular pertussis vaccine differs from whole cell vaccines in that it contains only those parts of the pertussis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry